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Background: Ocular complications of herpes zoster ophthalmicus (HZO) may lead to substantial visual impairment.
The purpose of this study was to characterize and analyze ocular involvement and visual outcome of HZO in
patients from Tunisia, North Africa. This study is a retrospective chart review of 51 eyes of 45 patients with HZO.
Results: Mean age was 44.5 years. Thirty patients (66.7%) were aged over 50 years. Twenty-four patients (53.3%) were
male and 21 patients were female (46.7%). There was no statistically significant difference in gender distribution. Initial
mean best corrected visual acuity (BCVA) was 20/50. Ocular manifestations included adnexal involvement (58.8%), keratitis
(31.4%), keratouveitis (31.4%), isolated anterior uveitis (AU) (29.4%), intraocular pressure elevation (23.5%), oculomotor nerve
palsy (5.8%), and optic neuritis (1.9%). Isolated AU (p < 0.001), isolated keratitis (p = 0.001), and intraocular pressure
elevation (p = 0.013) were more likely to be concomitant to HZO active skin disease, while keratouveitis occurred more
likely more than 1 month after HZO eruption (p < 0.001). AU and keratouveitis were more likely to be associated with
age ≥ 50 years (p = 0.001 and p = 0.02, respectively). Ocular complications included neurotrophic keratopathy (1.9%),
corneal opacity (5.9%), secondary glaucoma (7.8%), optic atrophy (1.9%), and postherpetic neuralgia (13.3%). Mean
follow-up was 12 months. Mean final BCVA was 20/32; it was ≥ 20/40 in 78.4% of the eyes.
Conclusions: Our study provided epidemiologic and clinical data of HZO in a Tunisian population. AU and keratitis
were the most common ocular complications. Neurotrophic keratopathy was scarce. The overall visual outcome is
good, with about three quarters of the treated patients maintaining VA of 20/40 or better.
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Herpes zoster ophthalmicus (HZO) is a reactivation of
the varicella zoster virus involving the ophthalmic division
of cranial nerve V. Herpes zoster affects 20% to 30% of the
population at some point in their lifetime, and approxi-
mately 10% to 20% of these individuals will have HZO [1].
Ocular involvement occurs in approximately 50% of HZO
patients in the absence of prompt preventive antiviral
therapy [1]. HZO is often associated with a chronic course
characterized by significant ocular morbidity and may
lead to significant visual impairment in the absence of
prompt and adequate treatment. Data on HZO from
North African region are lacking.* Correspondence: moncef.khairallah@rns.tn
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in any medium, provided the original work is pThe purpose of the present study was to characterize
and analyze ocular involvement and visual outcome of
HZO in patients from Tunisia, North Africa.Methods
The charts of 45 consecutive patients (51 eyes) with
HZO managed at the Department of Ophthalmology at
Fattouma Bourguiba University Hospital of Monastir,
Tunisia, from 1 January 2000 to 31 January 2012 were
reviewed. The diagnosis of acute HZO was based on the
presence of a primary vesiculomacular and dysesthetic skin
rash within the ophthalmic dermatome. All patients were
referred to our department from emergency department or
by ophthalmologists. Patients were questioned concerning
the history of the present illness, compromised immunean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and topical or systemic antiviral therapy at presentation,
renal failure, moderate or severe hypertension, diabetes
mellitus, and previous relevant eye diseases such as chronic
uveitis, keratitis, cataract, and glaucoma. All patients under-
went detailed ophthalmic examination including adnexae
examination, ocular motility, Snellen best corrected visual
acuity (BCVA), slit-lamp examination, and fluorescein test.
Adnexal involvement, including lid edema, blepharocon-
junctivitis with macular rash involving the eyelids, conjunc-
tival injection, vesicles, and petechial hemorrhages, was
sought. Corneal sensitivity testing by comparison of a
light touch with a cotton wool strand against the normal
fellow eye was performed and recorded as normal, reduced,
or absent. Grading of intraocular inflammation using
standardization of uveitis nomenclature (SUN) working
group criteria [2], tonometry, and dilated fundus exam-
ination with noncontact and contact lenses was also
performed for all patients.
Ocular manifestations were defined as any ocular disease
secondary to HZO. Intraocular pressure (IOP) elevation
was defined as IOP ≥ 22 mmHg. The type of uveitis, onset,
duration, and course was classified according to the
SUN working group criteria [2]. Keratitis was divided
into epithelial keratitis and stromal keratitis. When keratitis
was associated to uveitis, we used the term keratouveitis.
Routine laboratory work-up including a complete blood
count, erythrocyte sedimentation rate, C-reactive protein
tests, and serum biochemical analysis was performed for
all patients. Patients with bilateral involvement or aged
less than 50 years underwent dermatologic and infectious
diseases specialized examinations as well as serological
examinations, including HIV antibodies and syphilis
serology.
The presence or absence of postherpetic neuralgia (PHN)
was also recorded. PHN was defined in our study as any
symptom of pain or the use of pain medication for ocular
symptoms documented in the medical record at least 3
months after onset of HZO [3].
Patients were divided into two groups: group I including
patients with no ocular complications related to HZO and
group II including patients with ocular complications
related to HZO. Group II was also divided into two
subgroups: group II1 including patients with ocular
complications concomitant to HZO and group II2 includ-
ing patients with ocular complications occurring at least 1
month after HZO (Table 1).
All patients were treated with intravenous acyclovir
10 mg/kg 3 times daily or oral valacyclovir 3 g/day for
7 to 10 days. Topical corticosteroids, cycloplegics, topical
antibiotics, topical beta-blockers, oral carbonic anhydrase
inhibitors, and analgesics were prescribed when indicated.
Patients with anterior uveitis (AU) received antiviral ther-
apy for 8 to 14 weeks along with topical corticosteroidtherapy tapering. The mean follow-up was 12 months
(range 9 to 51).
Data entry and statistical analyses were performed using
Windows-based SPSS statistical software. Proportions
were compared between groups using the chi-square or
Fisher's exact test, as appropriate. Association between
variables was considered statistically significant for a
confidence level of 95% (p ≤ 0.05).
Results
Demographic data of our patients are given in Table 2.
Mean age was 44.5 years (range 12 to 77). Thirty patients
(66.7%) were aged over 50 years. There was no statistically
significance in gender distribution in patients aged less or
over 50 year old (p = 0.214) or in mean age between
genders (p = 0.615). HZO was unilateral in 39 patients
(86.7%). HZO affected the right eye in 21 patients (46.6%),
the left eye in 18 patients (40%), and both eyes in 6
patients (13.3%). Associated systemic diseases included
diabetes mellitus (9 patients; 20%), systemic hypertension
(8 patients; 17.8%), and dyslipidemia (2 patients; 4.4%).
Used medication included long-term corticosteroid therapy
for back pain (1 patient; 2.2%) and immunosuppressive
therapy for leukemia (1 patient; 2.2%) or for renal trans-
plantation (1 patient; 2.2%). Serology testing revealed HIV
infection in 2 patients (4.4%).
Of 6 patients with bilateral simultaneous HZO, 2 had
diabetes, 2 were under immunosuppressive therapy and
1 had HIV infection, and the past medical history was
unremarkable in the remaining patient.
Ocular symptoms included a red and painful eye in 42
patients (93.3%), blurred vision in 44 eyes (86.2%), and
diplopia in 3 patients (6.7%). Initial BCVA ranged from
20/200 to 20/20 (mean 20/50). It was < 20/200 in 7 eyes
(13.7%) and ≥ 20/40 in 15 eyes (29.4%). Group I in-
cluded 4 eyes (7.8%) of 4 patients and group II 47 eyes
(92.2%) of 41 patients, divided into group II1 (32 eyes;
62.7%) and group II2 (15 eyes; 29.5%) (Table 1).
Ocular manifestations included adnexal involvement
(30 eyes; 58.8%), AU (31 eyes; 60.7%), keratitis with
corneal hypoesthesia (16 eyes; 31.4%), oculomotor nerve
palsy (3 eyes; 5.8%), and optic neuritis with optic disc
edema (1 eye; 1.9%). No case of retinal involvement was
recorded in our patients.
Adnexal involvement included lid edema (30 eyes;
58.8%), subconjunctival hemorrhage (23 eyes; 45.1%),
and vesicular conjunctivitis (8 eyes; 25.8%).
Corneal hypoesthesia was recorded in 16 eyes (31.4%).
Corneal involvement included stromal keratitis in 8 eyes
(15.6%), epithelial keratitis in 5 eyes (9.8%), and concomi-
tant superficial and stromal keratitis in 3 eyes (5.8%).
Endotheliitis was not recorded in any affected eye.
Keratouveitis and isolated AU were observed respect-
ively in 16 eyes (31.4%) and in 15 eyes (29.4%). AU was
Table 3 Ocular complications associated with herpes
Table 1 Distribution of patients
Groups Number of eyes N = 51 %
Group I: patients with no ocular complications related to HZO 4 7.8
Group II: patients with ocular complications related to HZO 47 92.2
Group II1: patients with ocular complications concomitant to HZO 32 62.7
Group II2: patients with ocular complications occurring at least 1 month after HZO 15 29.5
HZO, herpes zoster ophthalmicus.
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chronic in 3 eyes (6.9%). Granulomatous keratic precipi-
tates were found in 18 eyes (58.1%). Focal iris atrophy
was recorded in 8 eyes (25.8%), Koeppe's nodules in 2
eyes (6.5%), pupillary distortion in 2 eyes (6.5%), and
posterior synechiae in 5 eyes (16.1%). IOP elevation was
noted in 12 eyes of 31 eyes with AU (23.5%) (Table 3).
Oculomotor nerve palsy included sixth cranial nerve
in 2 eyes (3.9%) and third cranial nerve in 1 eye (1.9%).
All patients received antiviral therapy 2 to 10 days
(average of 4 days) after the onset of ocular symptoms.
Keratitis gradually improved in all patients. There was
neurotrophic keratopathy in 1 eye (1.9%) of a patient
aged over 50 years and corneal opacity in 3 eyes (5.9%).
IOP elevation was controlled with medical therapy in 8
(15.7%) of the 12 eyes with IOP elevation. Four eyes
(7.8%) developed secondary glaucoma with optic disc
cupping and visual field defects.
Oculomotor nerve palsy gradually resolved within few
months in all 3 eyes initially involved. The case of optic
neuritis developed optic disc atrophy with deep VA loss.Table 2 Demographic characteristics and distribution of
patients with herpes zoster ophthalmicus
Number of patients N = 45 %
Age
Mean age 44.5 years (range 12 to 77)
Intervals
<50 15 33.3










Immunosuppressive therapy 2 4.4
Long-term corticosteroid therapy 1 2.2
HIV infection 2 4.4Mean final BCVA was 20/32 (range 20/400 to 20/20). It
was < 20/200 in 4 eyes (7.8%) and ≥ 20/40 in 40 eyes
(78.4%).
Our statistical analysis showed that patients from
group II1 are more likely to have isolated AU (p < 0.001),
isolated keratitis (p = 0.001), and IOP elevation (p = 0.013)
than patients with ocular complications occurring at least 1
month after HZO. However, keratouveitis occurred more
likely in group II2 (p < 0.001). AU and keratouveitis were
more likely to be associated with age ≥ 50 years (p = 0.001
and p = 0.02, respectively). There was no statistically signifi-
cant relationship between ocular complications of HZO
and gender (Table 4). PHN was recorded in 6 patients
(13.3%).
Discussion
The estimates of herpes zoster ranged between 320 and
410 per 100,000 person-years [4]. A recent study from
the Pacific region estimates the overall incidence rate ofzoster ophthalmicus
Number of eyes N = 51 %
Lid edema 30 58.8
Subconjunctival hemorrhage 23 45.1
Vesicular conjunctivitis 8 15.7
Corneal hypoesthesia 16 31.4
Keratitis 16 31.4
Epithelial keratitis 5 9.8
Stromal keratitis 8 15.7
Epithelial and stromal keratitis 3 5.9
Anterior uveitis only 15 29.4
Keratouveitis 16 31.4
Iris atrophy 8 15.7
Posterior synechiae 5 9.8
Pupillary distortion 2 3.9
IOP elevation 12 23.5
Glaucoma 4 7.8
Neurotrophic keratopathy 1 1.9
Oculomotor nerve palsy 3 5.9
Optic neuritis 1 1.9
IOP, intraocular pressure.
Table 4 Correlations between ocular complications in herpes zoster ophthalmicus groups, age, and gender
Ocular involvement Group Age (years) Gender Total
II1 % II2 % p value ≥50% <50% p value Female % Male % p value
Anterior uveitis 38.3 27.66 0.27 45.10 15.69 0.001* 33.33 27.45 0.51 31
Isolated anterior uveitis 31.91 0 <0.001* 19.61 9.80 0.16 21.57 7.84 0.051 15
Keratouveitis 6.38 27.66 <0.001* 23.53 7.84 0.02* 17.65 13.73 0.58 16
Isolated keratitis 29.79 4.26 0.001* 15.69 15.69 1 11.76 19.61 0.27 16
IOP elevation 21.28 4.26 0.013* 15.69 7.84 0.21 9.80 13.73 0.53 12
Oculomotor nerve palsy 6.38 0 0.24 5.88 0 0.24 3.92 1.96 1 3
Iris atrophy 6.38 10.64 0.71 13.73 1.96 0.07 11.76 3.92 0.26 8
IOP, intraocular pressure. *statistically significant p values.
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mately 10% of all estimates of herpes zoster overall [5].
In our study, 66.7% of patients were aged over 50
years, and 53.3% of patients were aged between 50 and
70 years. Previous studies showed that the incidence of
HZO increases significantly with age [1,5]. A recent case
series reports that HZO affects similarly individuals aged
younger than or older than 60 years, with the most com-
mon decade of onset between age 50 and 59 years [6]. In a
recent study, the incidence rate for the subgroup of the
population older than 65 years was approximately five
times that of the rest of the population [5]. Increased age
has been associated with a decrease in cell-mediated im-
munity, which is a crucial factor to avoid reactivation of
the latent varicella zoster virus.
Ghaznawi et al. [6] showed that younger individuals
were more likely to be healthy, with predisposing condi-
tions such as immunosuppressive treatment, cancer, and
HIV infection present in only 11.1% of patients who
were younger at onset. In our study, immunosuppressive
therapy and HIV infection were recorded in 3 (20%) of
15 patients aged less than 50 years.
The results of our study, consistent with data from a
previous report [5], show no significant difference in HZO
incidence between men and women overall and between
specific age groups. However, some other studies found
significant differences between incidence rates for men
and women within specific age groups, but there was
limited evidence of a significant difference overall between
incidence rates for men and women [4,7].
In the current study, a high incidence of ocular in-
volvement due to HZO (92.2%) was found. This may
be explained by a bias selection since, in our hospital,
the majority of HZO cases without ocular complaints
are usually referred to infectious disease specialists or
dermatologists.
AU, with or without associated keratitis, was the most
common ocular manifestation of HZO in our series,
occurring in 60.8% of eyes, followed by epithelial and/or
stromal keratitis recorded in 31.4% of eyes. Similarly, in
a study including 73 immunocompetent patients fromthe Netherlands during a period of 6 months follow-up,
AU was reported in 43.8% of eyes at initial examination,
followed by stromal keratitis in 30.1% of eyes [8]. In
another study, AU was recorded in 46.6% of cases and
keratitis in 76.2% of cases [9]. In a series of 18 younger
than 40 years old patients with HZO, AU was recorded
in 50% of cases and stromal keratitis in 22% of cases
[10]. In a recent study from the Pacific Islanders, a
lower rate of AU was recorded (6% of cases); however,
keratitis was recorded in 28.3% of cases [5]. In the latter
study, all patients, with or without ocular involvement,
were included; this may explain the lower proportion
of AU.
In the current study, isolated AU and isolated keratitis
were more likely to be concomitant to HZO eruption
(p < 0.001 and p = 0.001, respectively); however, kera-
touveitis is more likely to occur at least 1 month after
HZO (p < 0.001). A recent study shows the risk of AU
increased significantly in the year following a diagnosis
of HZO [11]. In addition, we found that both isolated
AU and keratouveitis were more likely to occur in
patients ≥ 50 years old (p = 0.001 and p = 0.02, respect-
ively), and there was no statistically significant association
between age and the occurrence of keratitis. In contrast, a
recent study comparing the course of HZO in patients'
younger vs. older than 60 years found that younger
patients had more episodes of delayed pseudodendriti-
form keratitis and AU compared with older patients.
However, prevalences of corneal perforation, corneal
thinning, cataract formation, and glaucoma were similar
between the two groups [6].
Despite the fact that about one third of our patients
developed keratitis, only one patient aged over 50
years old developed neurotrophic keratopathy. This
may be explained by the early antiviral therapy in our
patients with an average of 4 days after the onset of
HZO. While Ghaznawi et al. [6] found that neuro-
trophic keratopathy affected 19.6% of all patients and
was more frequent in older patients. Similarly, Liese-
gang et al. [12] reported a 25% prevalence of neuro-
trophic keratitis.
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5.8% of eyes with complete resolution during follow-up.
The reported incidence of extraocular muscle palsies in
HZO ranged between 7% and 31% [13,14], but many
cases are asymptomatic and usually transient. The third
oculomotor nerve is most commonly affected, followed
by the abducens nerve and the trochlear nerve [15].
Ophthalmoplegia was also reported [14,16].
In our study, optic neuritis was recorded in only one
eye. It is very rare sequelae of HZO, that may occur
simultaneously to the acute vesicular rash or, more fre-
quently, as a postherpetic complication, up to 10 weeks
after disease onset [17,18]. Optic neuritis is characterized
by low vision and central visual field defects, with an optic
nerve that looks initially normal or edematous, and which
progresses to optic atrophy leading to visual loss like in
our patient. A good recovery of HZO optic neuritis with
systemic acyclovir and steroid has been also reported [18].
The overall visual outcome was relatively good in our
series, with 78.4% of eyes having a final BCVA ≥ 20/40,
and only 7.8% of affected eyes were with final BCVA < 20/
200. Causes of low vision included optic disc atrophy
related to optic neuritis, neurotrophic keratopathy, and
corneal opacity. Zaal et al. [8] reported a final VA > 20/
25 in 90.4% of cases at 6 months follow-up. As well,
Gupta et al. [10] reported a final BCVA of 20/40 or better
in 90% of immunocompetent subjects younger than 40
years old. In a series of ten healthy children with HZO,
final BCVA was 20/20 in 80% of cases [19]. In a prospect-
ive study, 56.3% of patients had a VA of 6/6 or better and
visual loss was associated to increasing age, positive
Hutchinson's sign, absent corneal sensation, corneal
epithelial lesions, and uveitis [20].
In this study, a lower rate of PHN (13.3%) was found than
those of previous studies [5,9,21]. A higher incidence
(17.8%) was reported by Ghaznawi et al. [6] in an American
series including 112 patients and was statistically sig-
nificantly higher in the group aged more than 60 years
old. As well, in a Pacific region study, PHN was
recorded in 20.9% of patients [5], with 64.3% of patients
older than 65 years. The main risk factor for PHN is
advancing age; other risk factors include severity of
acute zoster pain and rash, a painful prodrome, and
ocular involvement [1,22]. It has been also shown that
patients with keratitis, conjunctivitis, or uveitis had a
higher risk of developing PHN compared with patients
who did not have these ocular features [5].
Our study presents some limitations, related to its
retrospective design, bias selection, and varying follow-
up. We acknowledge that the use of final VA introduces
a potential bias because the disease may be recurrent
and continue to cause loss of VA beyond the time the
outcome is reported. In addition to these limits, a major
drawback is the potential bias selection.Conclusions
Our study provided epidemiologic and clinical data of
HZO in a Tunisian population. AU and keratitis were
the most common ocular manifestations. Neurotrophic
keratopathy was scarce.
The overall visual outcome is good, with about three
quarters of the treated patients maintaining VA of 20/40
or better.
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